Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial. (2018)

First Author: Lyon PC
Attributed to:  OxCD3: Oxford Centre for Drug Delivery Devices funded by EPSRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s1470-2045(18)30332-2

PubMed Identifier: 30001990

Publication URI: http://europepmc.org/abstract/MED/30001990

Type: Journal Article/Review

Volume: 19

Parent Publication: The Lancet. Oncology

Issue: 8

ISSN: 1470-2045